To date, several antibodies, such as cytokeratin 19 (CK19), CD10, Hep Par 1, AFP, CA19-9, MOC31, glypican-3 and CEA, have been used to differentiate between the two malignant tumor types (1–3). This evidence concerns the gene KRT19 and cancer.